An experimental mRNA vaccine tested on 16 pancreatic cancer patients at Memorial Sloan Kettering Cancer Center in New York achieved remarkable results: seven of eight responders survived four to six years post-surgery, dramaticall
← News
Medicine Breakthroughs Medicine Breakthroughs Health
Commentary: Potential pancreatic cancer treatment breakthrough should be celebrated | The Bulletin
13% % Conventional 5-year survival rate
7 Of 8 patients Trial responders surviving 4-6 years post-surgery
50% % Immune response rate in trial
16 patients Trial cohort size
From 13% To 88% survival rate improvement
7 Of 8 Patients trial responders surviving